Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun;74(8):945-50.
doi: 10.1007/s40265-014-0230-8.

Luseogliflozin: first global approval

Anthony Markham  1 , Shelley Elkinson
Affiliations

Luseogliflozin: first global approval

Anthony Markham et al. Drugs. 2014 Jun.

Abstract

Luseogliflozin [Lusefi(®) (Japan)] is an orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor developed by Taisho Pharmaceutical for the treatment of patients with type 2 diabetes mellitus (T2DM). The drug has received its first global approval for this indication in Japan, either as monotherapy or in combination with other antihyperglycaemic agents. This article summarises the milestones in the development of luseogliflozin leading to this first approval for the treatment of T2DM.

PubMed Disclaimer

References

    1. Curr Med Res Opin. 2014 Jul;30(7):1245-55 - PubMed
    1. J Med Chem. 2010 Apr 22;53(8):3247-61 - PubMed
    1. Curr Med Res Opin. 2014 Jul;30(7):1231-44 - PubMed
    1. Br J Pharmacol. 2011 Sep;164(1):181-91 - PubMed
    1. Ann Intern Med. 2013 Aug 20;159(4):262-74 - PubMed

MeSH terms

Substances

LinkOut - more resources